News
TTNP
--
0.00%
--
Titan Medical Granted U.S. Patent Titled 'Alignment difference safety in a master-slave robotic system'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6826&f=G&l=50&d=PTXT&p=137&S1=20210831&OS=20210831&RS=20210831
Benzinga · 08/31 13:53
Here's Why Titan Pharmaceuticals (NASDAQ:TTNP) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 08/20 18:52
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
10 Pharma Companies Making Treatment for Opioid Overdose
In this article, we discuss the 10 pharma companies making treatment for opioid overdose. If you want to skip our detailed analysis of these stocks, go directly to the 5 Pharma Companies Making Treatment for Opioid Overdose. On July 21, a group of four sta...
Insider Monkey · 08/04 13:34
BRIEF-Titan Announces Positive Results From The First Studies Of TP-2021 Implant
reuters.com · 06/23 12:34
Titan Pharma reports positive TP-2021 implant results in animal model of chronic pruritus
Titan Pharmaceuticals (TTNP) announces that the in vivo study, ProNeura-based implant TP-2021 in an itch-induced mouse model, has demonstrated the potential to provide extended efficacy and durability in the treatment
Seekingalpha · 06/23 12:32
Healthcare names dominate premarket gainers
SeaChange International (SEAC) +26% on insider buying.ReTo Eco-Solutions (RETO) +21% after announcing new iron tailings project.Achieve Life Sciences (ACHV) +17%.Jiuzi Holdings, Inc. (JZXN) +15%.Tiziana Life Sciences PLC (TLSA) +11% on agreement with FHI
Seekingalpha · 06/23 12:23
Titan Announces Results From First Studies Of TP-2021 Implant In Established Animal Model Of Chronic Pruritus
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based implant in an established
Benzinga · 06/23 12:08
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus
/PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induce...
PR Newswire - PRF · 06/23 12:00
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 06/04 12:11
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 04/16 12:00
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14)
Benzinga · 04/15 11:49
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 04/14 11:51
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 04/13 12:16
Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission ("SEC").
PR Newswire · 03/31 20:30
Immunome, Avinger leads healthcare gainers; MEDNAX, ReWalk Robotics among major losers
Gainers: Immunome (IMNM) +93%, Avinger (AVGR) +33%, Titan Pharmaceuticals (TTNP) +17%, GBS (GBS) +15%, VistaGen Therapeutics (VTGN) +15%.Losers: MEDNAX (MD) -23%, ReWalk Robotics (RWLK) -21%, Shineco (TYHT) -19%, Check-Cap (CHEK) -15%, Advaxis (ADXS) -12%.
Seekingalpha · 02/18 16:01
TWLO, RIGL, ONTX and MACK among premarket gainers
Greenland Technologies Holding Corporation (GTEC) +186% on signing co-operation agreement with SOCMA.Immunome (IMNM) +152% on discovery of antibodies neutralizing SARS-CoV-2 variants.Avinger (AVGR) +57%.Heritage Global (HGBL) +42%.U.S. Well Services (USWS)...
Seekingalpha · 02/18 13:26
BRIEF-Positive Early Study Results Help Pave Wave For Titan Pharmaceuticals To Move Forward With Its JT-09 ProNeura Development Program
reuters.com · 02/01 12:37
Titan Pharmaceuticals Says Studies Of Its Kappa Opioid Agonist Peptide, JT-09, 'demonstrated high potency and specificity for the human kappa-opioid receptor'
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency
Benzinga · 02/01 12:35
Titan Pharmaceuticals -3% on pricing of $9.7M direct offering
Titan Pharmaceuticals ([[TTNP]] -2.9%) enters into a securities purchase agreement to purchase ~$9.7M of its common stock and warrants in a registered direct offering.The combined purchase price for one share
Seekingalpha · 01/15 14:43
Webull provides a variety of real-time TTNP stock news. You can receive the latest news about Titan Pharma through multiple platforms. This information may help you make smarter investment decisions.
About TTNP
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.